Hideyuki Akaza

13.4k total citations · 1 hit paper
517 papers, 9.7k citations indexed

About

Hideyuki Akaza is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Hideyuki Akaza has authored 517 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Pulmonary and Respiratory Medicine, 190 papers in Surgery and 96 papers in Oncology. Recurrent topics in Hideyuki Akaza's work include Prostate Cancer Treatment and Research (141 papers), Bladder and Urothelial Cancer Treatments (132 papers) and Prostate Cancer Diagnosis and Treatment (88 papers). Hideyuki Akaza is often cited by papers focused on Prostate Cancer Treatment and Research (141 papers), Bladder and Urothelial Cancer Treatments (132 papers) and Prostate Cancer Diagnosis and Treatment (88 papers). Hideyuki Akaza collaborates with scholars based in Japan, United States and France. Hideyuki Akaza's co-authors include Koji Kawai, Shiro Hinotsu, Toru Shimazui, Naoto Miyanaga, Seiji Naito, Kenkichi Koiso, Mizuki Onozawa, Yoshihiko Hirao, Kazunori Hattori and Taiji Tsukamoto and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hideyuki Akaza

498 papers receiving 9.4k citations

Hit Papers

Oral Relugolix for Androg... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    2020 259 citations Hideyuki Akaza et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hideyuki Akaza Japan 50 3.5k 3.1k 2.7k 1.8k 1.2k 517 9.7k
Tomonori Habuchi Japan 48 2.6k 0.7× 3.0k 1.0× 3.7k 1.4× 2.2k 1.3× 1.5k 1.3× 468 9.6k
Phyllis J. Goodman United States 45 6.8k 1.9× 2.0k 0.7× 2.3k 0.9× 3.5k 2.0× 1.9k 1.6× 160 13.2k
Georg Bartsch Austria 65 4.7k 1.3× 3.0k 1.0× 2.9k 1.1× 1.6k 0.9× 1.2k 1.0× 299 11.9k
Gregory T. MacLennan United States 59 4.8k 1.4× 3.5k 1.2× 5.0k 1.9× 2.2k 1.3× 2.2k 1.8× 321 11.4k
David F. Paulson United States 43 4.6k 1.3× 2.6k 0.9× 2.1k 0.8× 1.1k 0.6× 900 0.8× 190 8.3k
Pierluigi Benedetti Panici Italy 63 1.2k 0.3× 3.9k 1.3× 2.8k 1.1× 3.6k 2.1× 1.3k 1.1× 566 16.0k
Cord Langner Austria 48 1.8k 0.5× 3.1k 1.0× 1.8k 0.7× 2.6k 1.5× 754 0.6× 223 8.7k
Henrik Grönberg Sweden 57 5.2k 1.5× 1.1k 0.4× 3.2k 1.2× 2.6k 1.5× 2.5k 2.1× 263 11.6k
Daniel P. Normolle United States 59 3.0k 0.8× 1.7k 0.6× 2.9k 1.1× 3.4k 2.0× 1.5k 1.3× 201 12.7k
Sonny L. Johansson United States 56 1.4k 0.4× 3.5k 1.2× 2.7k 1.0× 2.3k 1.3× 1.1k 0.9× 204 9.1k

Countries citing papers authored by Hideyuki Akaza

Since Specialization
Citations

This map shows the geographic impact of Hideyuki Akaza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideyuki Akaza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideyuki Akaza more than expected).

Fields of papers citing papers by Hideyuki Akaza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideyuki Akaza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideyuki Akaza. The network helps show where Hideyuki Akaza may publish in the future.

Co-authorship network of co-authors of Hideyuki Akaza

This figure shows the co-authorship network connecting the top 25 collaborators of Hideyuki Akaza. A scholar is included among the top collaborators of Hideyuki Akaza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideyuki Akaza. Hideyuki Akaza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sugimoto, Mikio, Yoshiyuki Kakehi, Shigeo Horie, Yoshihiko Hirao, & Hideyuki Akaza. (2021). A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study. Japanese Journal of Clinical Oncology. 52(2). 187–196. 4 indexed citations
2.
Tatsugami, Katsunori, Mototsugu Oya, Koki Kabu, & Hideyuki Akaza. (2018). Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis. British Journal of Cancer. 119(2). 241–247. 10 indexed citations
3.
Akaza, Hideyuki. (2016). What is the Asian Consensus Statement on NCCN clinical practice guidelines in oncology (NCCN-ACS)?. Japanese Journal of Clinical Oncology. 46(4). 299–302. 8 indexed citations
4.
Saijo, Nagahiro, et al.. (2012). [Safety and efficacy of docetaxel in prostate cancer patients: based on the post-marketing surveillance in Japan].. PubMed. 39(4). 551–62. 2 indexed citations
5.
Naito, Seiji, Masatoshi Eto, Nobuo Shinohara, et al.. (2010). Multicenter Phase II Trial of S-1 in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 28(34). 5022–5029. 17 indexed citations
6.
White, Dorothy A., Philippe Camus, Masahiro Endo, et al.. (2010). Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. American Journal of Respiratory and Critical Care Medicine. 182(3). 396–403. 156 indexed citations
7.
Takaoka, Eiichiro, Shiro Hinotsu, Akira Joraku, et al.. (2010). Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: A single institutional retrospective long‐term follow‐up study. International Journal of Urology. 17(7). 623–628. 17 indexed citations
8.
9.
Akaza, Hideyuki. (2010). Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness. Cancer Science. 102(1). 51–56. 49 indexed citations
10.
Shimazui, Toru, Kazuhiro Yoshikawa, Kazuhiko Uchida, et al.. (2007). Prediction of in vitro response to interferon‐α in renal cell carcinoma cell lines. Cancer Science. 98(4). 529–534. 3 indexed citations
11.
Kai, Hirayasu, K Yamagata, Joichi Usui, et al.. (2005). Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy. Journal of Nephrology. 18(4). 436–441. 5 indexed citations
12.
Shimazui, Toru, et al.. (2002). Telomerase Is Upregulated in Irreversible Preneoplastic Lesions during Bladder Carcinogenesis in Rats. Japanese Journal of Cancer Research. 93(5). 495–500. 6 indexed citations
13.
Miyanaga, Naoto, Hideyuki Akaza, Toshiyuki Okumura, et al.. (2000). A bladder preservation regimen using intra‐arterial chemotherapy and radiotherapy for invasive bladder cancer: A prospective study. International Journal of Urology. 7(2). 41–48. 34 indexed citations
14.
Kuroda, M., T Kotake, Hideyuki Akaza, Shiro Hinotsu, & Tadao Kakizoe. (1998). Efficacy of Dose-intensified MEC (Methotrexate, Epirubicin and Cisplatin) Chemotherapy for Advanced Urothelial Carcinoma: a Prospective Randomized Trial Comparing MEC and M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin). Japanese Journal of Clinical Oncology. 28(8). 497–501. 36 indexed citations
15.
16.
Uchida, Yuusuke, Hideyuki Akaza, Toru Shimazui, et al.. (1996). Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy comparative study by the cross-over trial. Gan to kagaku ryōhō. 23(1). 81–86. 2 indexed citations
17.
Ota, Takashi, Toru Shimazui, Shiro Hinotsu, et al.. (1995). Primary signet ring cell carcinoma of the bladder effectively treated with intra-arterial chemotherapy and radiation therapy: A case report. 57(9). 1019–1023. 7 indexed citations
18.
Ohtani, Mikinobu, et al.. (1991). INTRA-ARTERIAL CISPLATIN AND CONCURRENT RADIATION FOR INVASIVE BLADDER CANCER. The Japanese Journal of Urology. 82(10). 1583–1587. 2 indexed citations
19.
Hara, T, et al.. (1982). Diminished helper-T-lymphocyte function in cancer patients.. PubMed. 28(1). 67–71. 2 indexed citations
20.
Umeda, T., H. Yokoyama, Kazuhiro Kobayashi, Hideyuki Akaza, & Tadao Niijima. (1980). Reduced membrane receptor activity of polymorphonuclear leucocytes of cancer patients.. PubMed. 26(5). 563–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomonori Habuchi Breakdown of academic impact, for papers by Phyllis J. Goodman Breakdown of academic impact, for papers by Georg Bartsch Breakdown of academic impact, for papers by Gregory T. MacLennan Breakdown of academic impact, for papers by David F. Paulson Breakdown of academic impact, for papers by Pierluigi Benedetti Panici Breakdown of academic impact, for papers by Cord Langner Breakdown of academic impact, for papers by Henrik Grönberg Breakdown of academic impact, for papers by Daniel P. Normolle Breakdown of academic impact, for papers by Sonny L. Johansson
Rankless by CCL
2026